Bullish
CVS (CVS); Walgreen (WAG); Commerce Bancorp (CBH); Principal Financial (PFG); Prudential (PRU); MetLife (MET); Conexant (CNXT); Omnova Solutions (OMN); Allegheny Tech (ATI); Fluor (FLR); Foster Wheeler (FWLT); ConocoPhillips (COP); Occidental Petroleum (OXY); Medco Health (MHS); Apple (AAPL); JDS Uniphase (JDSU); NMT Medical (NMTI) and Evergreen Solar (ESLR).
Bearish
PNC Financial (PNC); Chicago Bridge & Iron (CBI); TurboChef (OVEN); Chevron (CVX); EarthLink (ELNK); Drew Industries (DW); Dell (DELL); Ciena (CIEN); and American Axle (AXL).

Cramer stuck by the buy call on Washington Group International (WGII). He told another viewer to ring the register on Zumiez (ZUMZ) which is near a 52-week high. Cramer complemented a third viewer on Powerwave (PWAV) as a play on growth in cell-phone users in India and China. Cramer thinks Powerwave rocks.

Cramer was out with bullish comments on ViroPharma (VPHM) tonight. Cramer mentioned how the stock got hammered on Tuesday after reporting lack luster earnings guidance. But that’s not something to worry about, Cramer said. The company is playing the “UPOD” game — under-promise on guidance and overdeliver on earnings, he said. Cramer thinks ViroPharma looks like a good buy after that selloff and he thinks the stock can trade as high as $30 to $40 a share. It’s time to consider buying a lot of it,” he said. The reason for Cramer’s bullishness: ViroPharma has a drug that could be the “next big thing,” he said. Much of ViroPharma’s current business is centered on the drug Vancocin, which combats certain bacterial infections. The company purchased the drug from Eli Lilly (LLY) for a pittance, some $120 million, Cramer noted. In contrast, the company posted nearly $126 million in sales of the drug last year alone, he said. Those sales should grow 30% just due to expected price increases, he said. Meanwhile, demand for the drug should grow another 10%, he said. That adds up to 27% to 35% growth, Cramer said, a forecast he called “conservative.” Cramer also mentioned that ViroPharma has another drug coming to markets called Maribavir which could help prevent infections related to organ transplants and could bring in $500 million in sales.

Cramer was out with bullish comments on Costco (COST) tonight. Cramer thinks the company is on fire and taking market share from BJ’s Wholesale Club (BJ). Cramer thinks COST is a must own retailer that is doing brilliant things and is a great candidate for a longer term investment (18 months). Cramer thinks the companies move into the top brand electronics markets with offering from Sony (SNE) and Samsung is bullish for Costco. Cramer also thinks that Costco offers the best warranty in retail, which allows consumers to return products years after they bought them for only the cost of membership. Consumers shopping for electronics products are going to sign up for new memberships to Costco, Cramer said. And once the company has those consumers as members, it can sell them the rest of the goods it carries, like giant jars of pickles, he said. Cramer thinks Costco is the next Best Buy (BBY).

Caller Question. A caller asked how much Costco’s move into electronics would affect Best Buy. Cramer said he had promised viewers that Best Buy wouldn’t be affected by a similar move into electronics by Wal-Mart. Now he isn’t so sure that Best Buy wont be affected by this move into electronics for Costco. He thinks it could hurt Best Buy’s PE ratio and the market may not pay up for Best Buy in the future.

Cramer recommended that investors read trade publications in order to get an edge on Wall Street. Cramer suggested that many of these publications can be very good sources of intel that you will not get anywhere else. Cramer recommended PR Week as a good source of information. An article this week spotlighted the small biotech companies helping big pharmaceutical makers develop new drugs. With the release of those new drugs, the biotech companies have a chance to raise their own profiles, the report said. Rising public awareness plays into the Cramer’s first law, he said: The more the public is aware of these companies, the higher their stock prices will go. “The more they raise their profiles … the more we should be willing to back up the truck*,” he said. Cramer mentioned that Nektar Therapeutics (NKTR) was mentioned in PR Week and left out of a New York Times report on a new drug from Pfizer that NKTR played a key role in developing. Two companies that stood out that were mentioned in that article were Nuvelo (NUVO) and Cambridge Antibody Tech (CATG). Nuvelo is in the final stages of developing a blood clot dissolver, Cramer noted. Although that could be a “gigantic catalyst” for the company’s stock, it will take a while for that to develop, he acknowledged. Cramer thinks the drop of 6% in the shares of Nuvelo on Monday could be providing a good place to get into the stock. Meanwhile, Cambridge Antibody is working with AstraZeneca (AZN) to develop anti-inflammatory treatments. But that’s not all: The company has a partnership with Genzyme (GENZ) to develop some new antibiotics and with Abbott Laboratories (ABT) to develop treatments for rheumatoid arthritis. “That’s a company worth being partnered up with,” Cramer said. Cramer also likes that Cambridge has $265 million in cash and little debt.

Caller Question. A caller asked if partnerships with smaller biotech companies could bring back the big pharma companies as good investments. Cramer stated that for Pfizer and Merck (MRK) the answer was no. As for Procter & Gamble (PG), Cramer thinks that is buy even though the caller just threw PG in with the other two.

Cramer was out with bullish comments on Sherwin-Williams (SHW) tonight and he was reminding viewers that he recommended the stock earlier in the week. Cramer said that a “bogus lawsuit” against the company regarding lead-based paints was creating a buying opportunity in the stock. On Tuesday, the judge in the suit denied a request for punitive damages against the company, which should limit the cost of the case to the paint maker, he noted. The stock jumped 7% on the news, closing regular trading Tuesday at $45.55. If the broader market hadn’t been down so much Tuesday, Sherwin-Williams’ stock would have hit $52, Cramer said. “It’s good to be right,” Cramer said.

Bullish

EDO (EDO), DRS Tech (DRS), Bookham (BKHM), Century Aluminum (CENX), Manitowoc (MTW), Celgene (CELG), Genentech (DNA) Black & Decker (BDK), MEMC Electronics (WFR), Peabody Energy (BTU), Blue Nile (NILE), and Google (GOOG).

Bearish

Valero Energy (VLO), Amylin Pharmaceuticals (AMLN), Syntroleum (SYNM), LeapFrog (LF), Lucent (LU), Intrado (TRDO), Alcoa (AA), Johnson & Johnson (JNJ), Snap-On (SNA), Whole Foods (WFMI), Juniper Networks (JNPR), and Cisco (CSCO)

An article on Monday in the Wall Street Journal that ranks companies is “going out of its way to loose you money,” according to Cramer. On the list were what they considered worst-performing stocks of the past 10 years. The absolute worst on the list Cramer wants you to own: Foster Wheeler (FWLT). While competiting in the same oil service sector as Halliburton (HAL), they are also set to benefit from the high price of oil. Additionally any further terrorism will give FWLT a shot at more contracts. After the stock quadrupled last May, Cramer called these rankings “idiotic.”

Greenberg joined Cramer today and immediately went into the story about him being subpoenaed regarding Overstock.com (OSTK). Cramer had also been subpoenaed. Greenberg thought it was ironic that the Securities and Exchange Commission is issuing a subpoenea for him when he does the same thing they do, “policing bad companies.”

Washington Group International (WGII) will “inspire for all the wrong reasons.” In looking for a company with which to play “dirty bombs and spent radiation” Cramer pointed to WGII. An amazing power and infrastructure business that includes construction, design and engineering operations. They are leading the race to build new Alaskan pipelines as well as a factor in many coal and power plant projects. The mining business is also involved here. URS (URS) is also a favorite in coal-to-diesel technology for Cramer.